Janssen

STELARA

Manufacturer:

Janssen

Stelara HCPCS:

J3357

HCPCS Code Descriptor:

Ustekinumab, for subcutaneous injection, 1 mg

Category:

J Code

Stelara NDCs:

57894-0061-03, 57894-0060-03, 57894-0060-02

Primary Type:

Immunology:Anti-TNF

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

57894-0060-02

About Stelara:

STELARA is an Immunology:Anti-TNF drug manufactured by Janssen and administered via the Subcutaneous route of administration. The J Code: J3357 is aligned to the drug STELARA.

Stelara for subcutaneous injection is a type of medication used to treat a variety of autoimmune disorders. It is often prescribed via subcutaneous injection for patients with plaque psoriasis or psoriatic arthritis. Stelara injection is what's known as an interleukin inhibitor and is thought to work by blocking certain proteins in the body that cause inflammations.

ACCESS PRICING AND MORE BY REGISTERING

J3357 Added Date:

January 1, 2011

J3357 Effective Date:

January 1, 2017

J3357 Termination Date:

HCPCS Active

Stelara billing and coding information can be found through Janssen at the link below:
Stelara patient assistance information can be found through the Johnson and Johnson Patient Assistance Foundation at the URL: http://www.jjpaf.org/
STELARA prescribing information can be found at the link below:
Information regarding STELARA’s side effects can be found at MedlinePlus